Discover
LUCD
Lucid Diagnostics Inc.
1.05
2 x 0.78
2 x 1.34
bid
ask
-
0.02
1.87%
2 @ 04:00 PM
1.07 +0.02 (1.90%)
| Ytd | -3.67% | |
| 1y | -4.55% |
1.04
day range
1.09
0.90
52 week range
1.63
| Open | 1.06 | Prev Close | 1.07 | Low | 1.04 | High | 1.09 | Mkt Cap | 200.31M |
| Vol | 642.77K | Avg Vol | 1.17M | EPS | -0.34 | P/E | N/A | Forward P/E | -1.12 |
| Beta | 1.42 | Short Ratio | 0.80 | Inst. Own | 4.18% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 1.04 | 200-d Avg | 1.15 | 1yr Est | 3.50 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-13 | 2024-09 | -0.16 | -0.2 | -0.04 | -25.00% |
| 2024-08-12 | 2024-06 | 0 | N/A | N/A | N/A |
| 2024-08-12 | 2024-06 | 0 | -0.2 | N/A | N/A |
| 2024-05-13 | 2024-03 | 0 | -0.21 | N/A | N/A |
| 2024-05-13 | 2024-03 | 0 | N/A | N/A | N/A |
| 2024-03-25 | 2023-12 | 0 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-09 | Ascendiant Capital | Upgrade | Buy | Buy |
| 2024-11-15 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
| 2024-11-14 | Canaccord Genuity | Upgrade | Buy | Buy |
| 2024-11-14 | Needham | Upgrade | Buy | Buy |
| 2024-09-10 | Ascendiant Capital | Upgrade | Buy | Buy |
| 2024-08-13 | Canaccord Genuity | Upgrade | Buy | Buy |
Profile
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-05-06 | AKLOG LISHAN | Chief Executive Officer | 1.17M | Stock Award(Grant) |
| 2024-05-06 | GORDON MICHAEL ADAM | General Counsel | 400.00K | Stock Award(Grant) |
| 2023-09-25 | LAPIDUS STANLEY N | Director | 101.59K | Sale |
| 2024-05-06 | MCGRATH DENNIS M | Chief Financial Officer | 1.04M | Stock Award(Grant) |
| 2024-05-06 | O'NEIL SHAUN | President | 526.76K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Luminus Management, LLC | 1.15M | 893.62K | 1.94% |
| 2024-09-29 | Vanguard Group Inc | 560.92K | 434.77K | 0.95% |
| 2024-09-29 | Geode Capital Management, LLC | 213.54K | 165.51K | 0.36% |
| 2024-09-29 | Nantahala Capital Management, LLC | 126.36K | 97.94K | 0.21% |
| 2024-09-29 | Lido Advisors, LLC | 100.02K | 77.52K | 0.17% |
| 2024-09-29 | Levin Capital Strategies, LP | 66.53K | 51.57K | 0.11% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 366.92K | 284.40K | 0.62% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 193.99K | 150.36K | 0.33% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 101.56K | 78.72K | 0.17% |
| 2024-10-30 | Fidelity Total Market Index Fund | 56.57K | 43.85K | 0.10% |
| 2024-10-30 | Fidelity Series Total Market Index Fund | 24.00K | 18.60K | 0.04% |
| 2024-10-30 | Fidelity NASDAQ Composite Index Fund | 12.87K | 9.98K | 0.02% |